Background And Objective: Due to the constraints of the COVID-19 pandemic, healthcare workers have reported acting in ways that are contrary to their moral values, and this may result in moral distress. This paper proposes the novel digital phenotype profile (DPP) tool, developed specifically to evaluate stress experiences within participants. The DPP tool was evaluated using the COVID-19 VR Healthcare Simulation of Stress Experience (HSSE) dataset (NCT05001542), which is composed of passive physiological signals and active mental health questionnaires. The DPP tool focuses on correlating electrocardiogram, respiration, photoplethysmography, and galvanic skin response with moral injury outcome scale (Brief MIOS).
Methods: Data-driven techniques are encompassed to develop a tool for robust evaluation of distress among participants. To accomplish this, we applied pre-processing techniques which involved normalization, data sanitation, segmentation, and windowing. During feature analysis, we extracted domain-specific features, followed by feature selection techniques to rank the importance of the feature set. Prior to classification, we employed k-means clustering to group the Brief MIOS scores to low, moderate, and high moral distress as the Brief MIOS lacks established severity cut-off scores. Support vector machine and decision tree models were used to create machine learning models to predict moral distress severities.
Results: Weighted support vector machine with leave-one-subject-out-cross-validation evaluated the separation of the Brief MIOS scores and achieved an average accuracy, precision, sensitivity, and F1 of 98.67%, 98.83%, 99.44%, and 99.13%, respectively. Various machine learning ablation tests were performed to support our results and further enhance the understanding of the predictive model.
Conclusion: Our findings demonstrate the feasibility to develop a DPP tool to predict distress experiences using a combination of mental health questionnaires and passive signals. The DPP tool is the first of its kind developed from the analysis of the HSSE dataset. Additional validation is needed for the DPP tool through replication in larger sample sizes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258128 | PMC |
http://dx.doi.org/10.1016/j.cmpb.2023.107645 | DOI Listing |
Healthcare (Basel)
January 2025
Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.
Background/objectives: Lifestyle coaches are integral to delivery of the National Diabetes Prevention Program (DPP); however, few studies have explored the role of the lifestyle coach in relation to participant success. This study aimed to develop a conceptual model of the factors that contribute to lifestyle coach performance and success.
Methods: A cross-sectional qualitative study including 82 semi-structured interviews with National DPP staff and participants between June 2020 and February 2022.
Curr Ther Res Clin Exp
December 2024
Clinical trial institutions, The First People's Hospital of Guangyuan, Guangyuan, Sichuan, China.
Background: Type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) are highly prevalent diseases that constitute enormous public health problems. The efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors in blood glucose control in T2DM patients with NAFLD has been established, but little is known about its effect on liver enzyme levels.
Objective: This meta-analysis aimed to evaluate the influences of DPP-4 inhibitors on alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in patients with T2DM and NAFLD.
Curr Org Synth
January 2025
Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Introduction: The development of efficient and sustainable catalytic methodolo-gies has garnered considerable attention in contemporary organic synthesis.
Methods: Herein, we present a novel approach employing the Cu@DPP-SPION catalyst for the synthesis of ethyl 4-(aryl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate derivatives. This versatile catalytic system incorporates copper nanoparticles supported on 4-(1H-imidazo[4,5-f][1,10]phenanthrolin-2-yl)benzoic acid-functionalized superparamagnetic iron oxide nanoparticles (SPIONs).
Eye Contact Lens
November 2024
Department of Optics, Pharmacology and Anatomy (K.J.M.-G., D.F., D.P.P.), University of Alicante, Alicante, Spain; and Advanced Clinic Optometry Unit (D.P.P.), Department of Ophthalmology, Medimar International Hospital, Alicante, Spain.
Purpose: To investigate the impact on distance and near contrast sensitivity (CS) after fitting multifocal contact lenses (MFCLs) for presbyopia correction according to the scientific evidence already published.
Methods: Three bibliographic search was conducted on PubMed, Web of Sciences, and Scopus. Inclusion criteria were articles written in English evaluating distance and/or near CS in presbyopic patients using MFCLs, controlled clinical trials, and articles published from 2000 to 2024.
Drug Metab Rev
December 2024
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, India.
Alogliptin is an oral hypoglycemic agent selective inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme. Inhibition of DPP-4 increases the levels of the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) by preventing their degradation. The main goal is to study the predicted and experimental properties of absorption, distribution, metabolism, and elimination (ADME), compare them, examine predicted targets, and understand the use of SwissADME in designing other drug molecules.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!